REGN - NASDAQ
Regeneron Pharmaceuticals, Inc.
$618.95
+2.7%Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
At a Glance
Live SnapshotRegeneron Pharmaceuticals, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Steady FCF growth indicates consistent cash generation improvement. On a positive trajectory.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Regeneron Pharmaceuticals, Inc. Cash Flow Statement
REGN • NASDAQ
| Regeneron Pharmaceuticals, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
4.5B | 4.4B | 4B | 4.3B | 8.1B | 3.5B | 2.1B | 2.4B | 1.2B | 895.5M | 636.1M | 348.1M | 424.4M | 750.3M | -221.8M | -104.5M | -67.8M | -82.7M | -105.6M | -102.3M | |
543.7M | 482.9M | 421M | 341.4M | 286.2M | 235.9M | 210.3M | 148.2M | 145.5M | 104.7M | 74.9M | 52.7M | 41.2M | 36.9M | 31.1M | 19.7M | 14.2M | 11.3M | 11.5M | 14.6M | |
-785.4M | -757.3M | -837.8M | -746.4M | -147.1M | 75.6M | -130.6M | -140M | 318.8M | -360.1M | -121.6M | -66.6M | 63.6M | -340.2M | 0.0 | 0.0 | -56K | 0.0 | 0.0 | 0.0 | |
993.7M | 982.8M | 885M | 725M | 601.7M | 432M | 464.3M | 427.4M | 507.3M | 559.9M | 459M | 307.2M | 198.4M | 94.2M | 56.1M | 39.9M | 31.3M | 32.5M | 0.0 | 0.0 | |
-810.6M | -82.2M | 266.3M | 599.8M | 181.7M | -135M | -29.3M | 12.1M | 63.6M | 57.6M | 52.6M | 19.6M | 45.3M | 57M | 10.4M | 293K | -382K | 2.2M | 34M | 17.9M | |
(0.0) | (743M) | (870.3M) | (1.5B) | (1.2B) | (188.1M) | (342.3M) | (205.6M) | (754.8M) | (481.4M) | (276.1M) | (59.8M) | (1.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (3.1M) | (0.0) | (0.0) | |
532.6M | -618.3M | -94.1M | -243.3M | -1.9B | -1.5B | -200.5M | -697M | -926.5M | 228.2M | 229.8M | 20.2M | -190.7M | -672.8M | -17.5M | 140.9M | -49.5M | -52.4M | 87.5M | 93M | |
5B | 4.4B | 4.6B | 5B | 7.1B | 2.6B | 2.4B | 2.2B | 1.3B | 1.5B | 1.3B | 752.4M | 588.6M | -74.6M | -141.7M | 96.3M | -72.2M | -89.1M | 27.4M | 23.1M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-1.2B | -755.9M | -926.4M | -590.1M | -551.9M | -614.6M | -429.6M | -383.1M | -272.6M | -511.9M | -677.9M | -333M | -156.3M | -49.3M | -57.2M | -99.7M | -97.3M | -34.9M | -18.4M | -2.8M | |
-3.3M | -16.5M | -54.9M | -230.3M | (551.9M) | (614.6M) | (429.6M) | (1.1B) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-11B | -16.6B | -11.6B | -7.5B | -7B | -3.2B | -3.2B | -1.8B | -1.3B | -809.4M | -557.1M | -564.2M | -577.3M | -470.4M | -240.4M | -612.2M | -200M | -581.1M | -594.4M | -456.9M | |
11.5B | 15B | 9.4B | 5.6B | 2.2B | 3.8B | 1.6B | 775.6M | 544.6M | 274.5M | 327.4M | 476.4M | 378.1M | 439.2M | 426.4M | 276.6M | 297.4M | 646.9M | 527.2M | 306.2M | |
0.0 | -105.6M | 0.0 | -1B | -551.9M | -614.6M | -429.6M | -1.1B | -26K | -41K | 0.0 | 0.0 | 0.0 | -552K | -277K | 1.1M | 50K | -50K | 0.0 | -1.6M | |
-629.1M | -2.5B | -3.2B | -3.8B | -5.4B | -70.6M | -2B | -1.5B | -1B | -1B | -907.6M | -420.8M | -355.5M | -81.1M | (128.5M) | -434.2M | (146K) | (30.8M) | -85.7M | -155.1M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-3.3B | -2.2B | -1.8B | -1B | -1B | -4B | -252.1M | -77.1M | -61.5M | -16.5M | 45.8M | -141.5M | -137.7M | -99.8M | 18.5M | 196.8M | 8.6M | 7.9M | 319.4M | 185M | |
0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 2B | 0.0 | 0.0 | 37.1M | -40.6M | -140.4M | -221.7M | -2M | -2.2M | 389.4M | 46.5M | 22.8M | -200.8M | 0.0 | 0.0 | |
-370.3M | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-4B | -3.6B | -2.9B | -2.5B | -2.7B | -6.5B | -463.9M | -191.6M | -301.7M | -143.2M | -160.5M | -267.6M | -195.1M | -163.3M | -25.1M | -3.8M | (0.0) | (0.0) | (0.0) | (0.0) | |
-10.3M | -33.4M | 0.0 | -445.7M | -1B | 2.6B | -188M | -187.2M | 0.0 | -516.6M | -168.2M | 144.7M | 16.8M | 4.3M | -23.7M | 0.0 | 0.0 | 0.0 | 0.0 | 390K | |
-3.7B | -2.2B | -1.8B | -1B | -1B | -2B | -252.1M | -77.1M | -24.4M | -700.4M | -262.8M | -218.5M | 72.2M | -97.6M | 384.2M | 243.3M | 31.4M | -192.9M | 319.4M | 185.4M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
300K | -700K | -400K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
634.7M | -248.8M | -381.6M | 221.3M | 690.8M | 577M | 150.1M | 655M | 277.5M | -273.9M | 160.4M | 113.1M | 305.3M | -253.3M | 371M | -94.5M | -40.7M | -251.1M | 261M | 53.4M | |
2.5B | 2.7B | 3.1B | 2.9B | 2.2B | 1.6B | 1.5B | 825.2M | 535.2M | 809.1M | 648.7M | 535.6M | 230.3M | 483.6M | 112.6M | 207.1M | 247.8M | 498.9M | 237.9M | 184.5M | |
3.1B | 2.5B | 2.7B | 3.1B | 2.9B | 2.2B | 1.6B | 1.5B | 812.7M | 535.2M | 809.1M | 648.7M | 535.6M | 230.3M | 483.6M | 112.6M | 207.1M | 247.8M | 498.9M | 237.9M | |
4.1B | 3.7B | 3.7B | 4.4B | 6.5B | 2B | 2B | 1.8B | 1B | 974M | 652.8M | 419.4M | 432.3M | -124M | -198.9M | -3.3M | -169.5M | -123.9M | 8.9M | 20.3M |
SEC Filings
REGN - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 08, 2026 | April 08, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 04, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | January 30, 2026 | January 30, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 12, 2026 | January 12, 2026 | 2026 | |
8-K 8-K 2025 N/A | October 28, 2025 | October 28, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 28, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | October 06, 2025 | October 06, 2025 | 2025 |
Related Guides
Continue your REGN research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.